Skip to main content
Qingdao Vland Biotech Inc. logo

Qingdao Vland Biotech Inc. — Investor Relations & Filings

Ticker · 603739 ISIN · CNE100003GX8 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 991 across all filing types
Latest filing 2026-05-22 Notice of Dividend Amou…
Country CN China
Listing Shanghai Stock Exchange 603739

About Qingdao Vland Biotech Inc.

http://www.vlandbiochem.com/

Qingdao Vland Biotech Inc. specializes in the research, development, and production of enzymes, probiotics, and animal health solutions. The company provides biological products for diverse applications, including animal nutrition, food processing, textiles, household care, and environmental protection. Its enzyme portfolio encompasses phytases, carbohydrases, and proteases designed to improve feed efficiency and industrial productivity. In the probiotics sector, the firm develops microbial strains for human health and livestock management. Additionally, the company offers veterinary vaccines and pharmaceutical products. By leveraging advanced biotechnology, the organization focuses on delivering sustainable alternatives to traditional chemical processes, aiming to enhance resource efficiency and reduce environmental impact across global supply chains.

Recent filings

Filing Released Lang Actions
青岛蔚蓝生物股份有限公司2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 97% confidence The document is an announcement by Qingdao Weilan Biology Co., Ltd. detailing the 2025 annual profit distribution scheme implementation, including per-share cash dividend, record date, ex-dividend date, payment date, and tax handling. This corresponds precisely to a Notice of Dividend Amount. It is not a full report but a specific dividend distribution announcement.
2026-05-22 Chinese
北京海润天睿律师事务所关于青岛蔚蓝生物股份有限公司2025年年度股东会的法律意见书
Regulatory Filings Classification · 92% confidence The document is a legal opinion letter issued by a law firm regarding the procedural validity, convening, attendance and voting outcomes of the company’s 2025 annual shareholders’ meeting. It does not itself constitute AGM presentation materials, a proxy solicitation statement, or a financial report, but rather is an attestation/certification of compliance with laws and the company’s bylaws. Under the “Certification Rule,” such attorney attestation letters are classified as general regulatory filings (RNS) rather than as the underlying report or meeting materials.
2026-05-15 Chinese
青岛蔚蓝生物股份有限公司关于完成董事会换届选举及聘任高级管理人员的公告
Board/Management Information Classification · 91% confidence The document is an announcement by Qingdao Azure Biological Co., Ltd. about the completion of a board re-election and the appointment of senior management personnel. It details the composition of the new board and the names/positions of appointed executives. This clearly matches the definition for Board/Management Information.
2026-05-15 Chinese
青岛蔚蓝生物股份有限公司关于公司第六届董事会第一次会议决议的公告
Board/Management Information Classification · 90% confidence The document is an official announcement of board resolutions from the company’s Board of Directors meeting, detailing elections and appointments of the Chairman, Honorary Chairman, and various senior management positions. This fits the definition of Board/Management Information (MANG). No financial statements or substantive data are present, and it is clearly a management change announcement.
2026-05-15 Chinese
青岛蔚蓝生物股份有限公司关于选举第六届董事会职工代表董事的公告
Board/Management Information Classification · 95% confidence The document is a corporate announcement detailing the election of an employee representative director to the company’s board of directors, including the person’s resume and term details. This constitutes a change in the company’s board composition. According to the classification definitions, announcements of changes in the board of directors fall under Board/Management Information (MANG).
2026-05-15 Chinese
青岛蔚蓝生物股份有限公司2025年年度股东会会议材料
AGM Information Classification · 100% confidence The document is titled as materials for the 2025 Annual General Meeting (AGM) of 青岛蔚蓝生物股份有限公司, dated May 15, 2026. It contains detailed agenda items for the AGM, including proposals for approval such as the 2025 Board Work Report, the 2025 Annual Report, profit distribution plan, remuneration plans, appointment of auditors, amendments to company bylaws, election of directors, and other governance matters. The document includes extensive meeting instructions, detailed proposals, and supporting annexes like the Board Work Report and remuneration management system. The content is clearly the presentation and materials prepared for the AGM to be discussed and voted on by shareholders. It is not the annual report itself, nor a voting result announcement, but the meeting materials for the AGM. The document length (15,000 characters) and detailed agenda confirm it is not a brief announcement or a certification. Therefore, the filing type is AGM Information (AGM-R).
2026-05-07 Chinese

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.